We use cookies for a better user experience. Read our Privacy Policy

I Agree

Rare Dermatological Disease Treatment Market Forecast Report, 2021-2031

Rare Dermatological Disease Treatment Market (Major Indication: Systemic Sclerosis [Scleroderma], Epidermolysis Bullosa [EB], Pemphigus Vulgaris, and Cutaneous Lupus Erythematosus; Treatment: Corticosteroids, Immunosuppressants, Anti-inflammatory Agents, Antibiotics, Analgesics, and Others; and Distribution Channel: Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2021-2031

Deep Investigation on Interactions Between COVID-19 and Systemic Sclerosis

The COVID-19 pandemic poses a serious challenge for the management of patients with different pre-existing conditions, including autoimmune diseases such as systemic sclerosis. Companies in the rare dermatological disease treatment market are under scrutiny for robust supply of treatments and medications such as antibiotics, immunosuppressants, and corticosteroids, among others, to support the health of patients.

Systemic sclerosis represents one of the most severe connective tissue diseases with multi-organ involvement, owing to concomitancy of fibrosing and microvascular alterations. Hence, companies in the rare dermatological disease treatment market are boosting their production capacities in medications to reduce morbidity and mortality rates. The deep investigation on the possible interactions between SARS-CoV-2 infection and a compromised host immune system might provide useful pathogenic and therapeutic insights into both coronavirus and systemic sclerosis.

rare dermatological disease treatment market infographic

To know the scope of our report Get a Sample on Rare Dermatological Disease Treatment Market

R&D Helps to Explore Novel Treatments for EB

The rare dermatological disease treatment market is expected to surpass US$ 6.17 Bn by 2031. Since there is no curative treatment for epidermolysis bullosa (EB), there is a need for advances in understanding molecular genetics and underlying pathomechanisms of different forms of EB. Companies are expected to team with researchers to deploy promising R&D for exploring novel treatments for EB.

Stakeholders and researchers are gaining a strong research base in topical medications for wound care in order to accelerate wound healing. This has the potential in wound care across different forms of EB.

Get a glimpse of the in-depth analysis through our Report Brochure

Rituximab Gains Prominence in Effective Pemphigus Vulgaris Treatment

The rare dermatological disease treatment market is estimated to clock a CAGR of 4.9% from 2021 to 2031. The therapeutic management of pemphigus vulgaris (PV) involves the combination of systemic corticosteroids and potentially corticosteroid-sparing immunosuppressive drugs, namely azathioprine and mycophenolate mofetil as the standard first-line therapy by most clinicians.

Manufacturers in the rare dermatological disease treatment market are bolstering their output capabilities of Rituximab in order to treat severe forms of pemphigus vulgaris. Patients initially treated with prednisone/prednisolone plus Rituximab and who have persistent active lesions are being recommended to increase the doses of prednisone/prednisolone. Moderate and severe types of pemphigus vulgaris are being treated with Rituximab administered as a monotherapy or associated with topical corticosteroids in patients with absolute contraindication to systemic corticosteroid therapy.

Therapeutic Patient Education Helps in Better Understanding of Systemic Sclerosis

The use of cyclophosphamide at very high doses during intensive conditioning procedures for myelosuppressive or myeloablative purposes, with or without antilymphocytic serum followed by autologous hematopoietic stem cell (HSC) transplantation has proved effective in the systemic sclerosis treatment. Companies in the rare dermatological disease treatment market are increasing their focus on these treatment options for severe and rapidly progressive forms of systemic sclerosis.

In order to improve patient quality of life, non-pharmacological therapies such as functional rehabilitation are being recommended to combat systemic sclerosis. Companies and healthcare providers in the rare dermatological disease treatment market are increasing awareness about therapeutic patient education (TPE) to obtain a better understanding of the disease.

rare dermatological disease treatment market segmentation

Expanding operations in future? To get the perfect launch ask for a custom report

Analysts’ Viewpoint

Given the unpredictable and threatening course of the COVID-19 pandemic, valuable prevention and management strategies are being implemented at healthcare facilities for systemic sclerosis patients. Therapeutic patient education is emerging as an effective strategy to acquire and maintain the skills to better manage systemic sclerosis. There is a need to limit common side effects usually associated with long-term immunosuppressive or corticosteroid treatment for pemphigus vulgaris. Companies in the rare dermatological disease treatment market should increase investments in research to develop novel treatment options for pemphigus vulgaris. Additional supportive treatments such as intralesional injections of corticosteroids are being considered for isolated lesions of oral mucosa, lips, and skin of pemphigus vulgaris patients.

Rare Dermatological Disease Treatment Market: Overview

  • According to Transparency Market Research’s latest report on the global rare dermatological disease treatment market for the historical period of 20172019 and forecast period of 20212031, increase in incidence of rare diseases and surge in research & development for orphan drugs are projected to drive the global rare dermatological disease treatment market during the forecast period
  • According to the report, the global rare dermatological disease treatment market was valued over US$ 3.66 Bn in 2020. It is anticipated to expand at a CAGR of 4.9% from 2021 to 2031.

Rise in Prevalence of Rare Dermatological Disease: Key Driver

  • According to the European Union, rare dermatological disease is defined as a rare disease with a prevalence of no more than 50 people per 100,000 population, while in the U.S. rare disease is defined as a condition that affects fewer than 200,000 individuals
  • According to the United States National Epidermolysis Bullosa Registry, the overall incidence and prevalence of epidermolysis bullosa is 19.6 and 11.07 cases per 1 million live births, respectively. Incidence and prevalence of epidermolysis bullosa simplex was 7.87 and 6 cases per 1 million live births, respectively.
  • According to the National Epidermolysis Bullosa Registry, the prevalence of epidermolysis bullosa in Norway is 54 cases per million live births, 7.8 cases per million live births in Japan, 15.4 cases per million live births in Italy, 10.3 cases per million live births in Australia, and 9.6 cases per million live births in Croatia
  • According to the Lupus Foundation of America, nearly 1.5 million people in the U.S. and 5 million to 6 million people across the global are affected with various form of lupus. Systemic lupus erythematosus affects about 70% of all cases of lupus.
  • Most people with lupus develop the disease between the ages of 15 and 44. Women are more prone to develop this disease compared to men. According to the Lupus Foundation of America, nine out of 10 adults with lupus are women and one in three lupus patients suffer from multiple autoimmune diseases.
  • According to WebMD LLC, pemphigus vulgaris has been reported to occur worldwide. Pemphigus vulgaris incidence varies from 0.5 to 3.2 cases per 100,000 population. Incidence of pemphigus vulgaris has increased in patients of Ashkenazi Jewish descent and those of Mediterranean origin.
  • Hence, rise in prevalence of diseases across the world is projected to drive the rare dermatological disease treatment market during the forecast period

Rich Pipeline for Rare Dermatological Disease Treatment to Boost Market

  • A large patient population suffers from various rare dermatological diseases with unmet medical needs, and the number is increasing across the globe. Leading pharmaceutical companies strive to address these unmet medical needs through new product development.
  • Large number of both small molecules and biologic products is under different phases of clinical trials for the treatment of rare diseases. Leading companies have made significant investments in clinical R&D and have established strategic partnerships and collaborations to accelerate new product development.
  • For instance, in 2019, Merck & Co., Inc., a global leader in autoimmune disease treatment, announced two potential candidates, Atacicept, and Evobrutinib, which are in phases 2 of clinical trials, to treat conditions such as systemic lupus erythematosus and other autoimmune disorders
  • Rise in investment in research & development programs by key players is likely to propel the market during the forecast period

High Cost of Drugs, Therapies to Hamper Global Market

  • Biologics are the most recent forms of treatment. Significant investments have been made in research in order to develop biologics and make them available to patients.
  • Most biologics are administered through parenteral route. This increases the cost of the treatment by adding the physician’s costs to the drugs cost.
  • According to the Lupus Foundation of America, the mean annual total cost for people with lupus (combining direct and indirect costs) can be as high as US$ 50,000
  • Moreover, lack of affordability for patients for certain drugs and therapies to treat scleroderma remains a major obstacle to improve patient access to these treatment options

Rare Dermatological Disease Treatment Market: Competition Landscape

  • This report profiles major players in the global rare dermatological disease treatment market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments
  • Leading players operating in the global rare dermatological disease treatment market include
    • Sanofi
    • GlaxoSmithKline plc
    • Novartis AG
    • Castle Creek Biosciences, Inc.
    • Merck & Co., Inc.
    • Bristol-Myers Squibb Company
    • Pfizer, Inc.
    • F. Hoffmann-La Roche Ltd.
    • Merck KGaA
    • Eli Lilly and Company
    • AbbVie, Inc.
    • Krystal Biotech, Inc.
    • Amryt Pharma plc

Rare Dermatological Disease Treatment Market: Key Developments

  • Key players in the global rare dermatological disease treatment market are engaged in regulatory approvals, development of new therapies or products, and acquisition & collaborative agreements with other companies. These strategies are likely to fuel the global rare dermatological disease treatment market. A few expansion strategies adopted by players operating in the global rare dermatological disease treatment market are:
    • In October 2020, Castle Creek Biosciencese, Inc. announced that first patient was dosed in the DeFi-RDEB phase 3 clinical trial evaluating debcoemagene autoficel (D-Fi), the company’s lead gene therapy candidate formerly designated FCX-007, in recessive dystrophic epidermolysis bullosa (RDEB)
    • In September 2020, Amryt Pharma plc announced positive top line results from its pivotal phase 3 EASE trial of FILSUVEZ (previously AP101/Oleogel-S10) for the treatment of dystrophic and junctional epidermolysis bullosa (“EB”)
    • In July 2020, Krystal Biotech announced the initiation of GEM-3 study, a multi-center, placebo-controlled, double-blinded, phase 3 clinical study of beremagene geperpavec (“B-VEC”, previously “KB103”) for the treatment of dystrophic epidermolysis bullosa (DEB) patients
    • In April 2020, Pfizer, Inc. announced that the European Commission (EC) approved RUXIENCE (rituximab), a biosimilar to MabThera (rituximab), for the treatment of non-Hodgkin’s lymphoma (NHL), chronic lymphocytic leukemia (CLL), rheumatoid arthritis (RA), granulomatosis with polyangiitis (GPA), and microscopic polyangiitis (MPA), and pemphigus vulgaris (PV)
    • In March 2019, Roche announced that the European Commission has approved MabThera (rituximab) for the treatment of adults with moderate to severe pemphigus vulgaris (PV), a rare condition characterized by progressive painful blistering of the skin and/or mucous membranes
    • In September 2018, Amryt Pharma plc announced that the U.S. Food and Drug Administration granted Investigational New Drug (“IND”) clearance for AP101. This enabled the company to begin opening the U.S. clinical trial sites as part of its ongoing global EASE phase III clinical trial in epidermolysis bullosa (“EB”).
  • The competition landscape section has been included in the report to provide readers with a dashboard view and a company market share analysis of key players operating in the global rare dermatological disease treatment market

Rare Dermatological Disease Treatment Market – Segmentation

Major Indication
  • Systemic Sclerosis (Scleroderma)
  • Epidermolysis Bullosa (EB)
  • Pemphigus Vulgaris
  • Cutaneous Lupus Erythematosus
Treatment
  • Corticosteroids
  • Immunosuppressants
  • Anti-inflammatory Agents
  • Antibiotics
  • Analgesics
  • Others
Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Interested in this report?
Get a FREE sample now!

Get Free Sample

*Get Sample Report (PDF) sent to your email within minutes

Frequently Asked Questions

What is the total market worth of rare dermatological disease treatment market?

Rare dermatological disease treatment market is expected to surpass US$ 6.17 Bn by 2031

What is the anticipated CAGR of the rare dermatological disease treatment market in the forecast period?

Rare dermatological disease treatment market is estimated to clock a CAGR of 4.9% from 2021 to 2031

What are the key driving factors for the growth of the rare dermatological disease treatment market?

Rare dermatological disease treatment market is driven by increase in incidence of rare diseases and surge in research & development for orphan drugs

Which is the rising prominent segment in the rare dermatological disease treatment market?

The systemic sclerosis segment dominated the global rare dermatological disease treatment market in 2020, and the trend is projected to continue during the forecast period

Who are the key players in the global rare dermatological disease treatment market?

Key players in the global rare dermatological disease treatment market include Sanofi, GlaxoSmithKline plc, Novartis AG, Castle Creek Biosciences, Inc., Merck & Co.

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Rare Dermatological Disease Treatment Market

4. Market Overview

    4.1. Introduction

        4.1.1. Segment Definition

    4.2. Overview

    4.3. Market Dynamics

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunities

    4.4. Global Rare Dermatological Disease Treatment Market Analysis and Forecast, 2017–2031

        4.4.1. Market Revenue Projections (US$ Mn)

5. Key Insights

    5.1. Pipeline Analysis

    5.2. Novel Therapies for Rare Dermatological Disease

    5.3. Key Industry Events (Mergers, Acquisitions, Partnerships, Collaborations, etc.)

    5.4. COVID-19 Pandemic Impact on Industry (Value Chain and Short / Mid / Long Term Impact)

6. Global Rare Dermatological Disease Treatment Market Analysis and Forecast, by Major Indication

    6.1. Introduction & Definition

    6.2. Key Findings / Developments

    6.3. Global Rare Dermatological Disease Treatment Market Value Forecast, by Major Indication, 2017–2031

        6.3.1. Systemic Sclerosis (Scleroderma)

        6.3.2. Epidermolysis Bullosa (EB)

        6.3.3. Pemphigus Vulgaris

        6.3.4. Cutaneous Lupus Erythematosus

    6.4. Global Rare Dermatological Disease Treatment Market Attractiveness, by Major Indication

7. Global Rare Dermatological Disease Treatment Market Analysis and Forecast, by Treatment

    7.1. Introduction & Definition

    7.2. Key Findings / Developments

    7.3. Global Rare Dermatological Disease Treatment Market Value Forecast, by Treatment, 2017–2031

        7.3.1. Corticosteroids

        7.3.2. Immunosuppressants

        7.3.3. Anti-inflammatory Agents

        7.3.4. Antibiotics

        7.3.5. Analgesics

        7.3.6. Others

    7.4. Global Rare Dermatological Disease Treatment Market Attractiveness, by Treatment

8. Global Rare Dermatological Disease Treatment Market Analysis and Forecast, by Distribution Channel

    8.1. Introduction & Definition

    8.2. Key Findings / Developments

    8.3. Global Rare Dermatological Disease Treatment Market Value Forecast, by Distribution Channel, 2017–2031

        8.3.1. Hospital Pharmacies

        8.3.2. Retail Pharmacies

        8.3.3. Online Pharmacies

    8.4. Global Rare Dermatological Disease Treatment Market Attractiveness, by Distribution Channel

9. Global Rare Dermatological Disease Treatment Market Analysis and Forecast, by Region

    9.1. Key Findings

    9.2. Global Rare Dermatological Disease Treatment Market Value Forecast, by Region

        9.2.1. North America

        9.2.2. Europe

        9.2.3. Asia Pacific

        9.2.4. Latin America

        9.2.5. Middle East & Africa

    9.3. Global Rare Dermatological Disease Treatment Market Attractiveness, by Country/Region

10. North America Rare Dermatological Disease Treatment Market Analysis and Forecast

    10.1. Introduction

        10.1.1. Key Findings

    10.2. North America Rare Dermatological Disease Treatment Market Value Forecast, by Major Indication, 2017–2031

        10.2.1. Systemic Sclerosis (Scleroderma)

        10.2.2. Epidermolysis Bullosa (EB)

        10.2.3. Pemphigus Vulgaris

        10.2.4. Cutaneous Lupus Erythematosus

    10.3. Market Value Forecast, by Treatment, 2017–2031

        10.3.1. Corticosteroids

        10.3.2. Immunosuppressants

        10.3.3. Anti-inflammatory Agents

        10.3.4. Antibiotics

        10.3.5. Analgesics

        10.3.6. Others

    10.4. North America Rare Dermatological Disease Treatment Market Value Forecast, by Distribution Channel, 2017–2031

        10.4.1. Hospital Pharmacies

        10.4.2. Retail Pharmacies

        10.4.3. Online Pharmacies

    10.5. North America Rare Dermatological Disease Treatment Market Value Forecast, by Country, 2017–2031

        10.5.1. U.S.

        10.5.2. Canada

    10.6. North America Rare Dermatological Disease Treatment Market Attractiveness Analysis

        10.6.1. By Major Indication

        10.6.2. By Treatment

        10.6.3. By Distribution Channel

        10.6.4. By Country

11. Europe Rare Dermatological Disease Treatment Market Analysis and Forecast

    11.1. Introduction

        11.1.1. Key Findings

    11.2. Europe Rare Dermatological Disease Treatment Market Value Forecast, by Major Indication, 2017–2031

        11.2.1. Systemic Sclerosis (Scleroderma)

        11.2.2. Epidermolysis Bullosa (EB)

        11.2.3. Pemphigus Vulgaris

        11.2.4. Cutaneous Lupus Erythematosus

    11.3. Europe Rare Dermatological Disease Treatment Market Value Forecast, by Treatment, 2017–2031

        11.3.1. Corticosteroids

        11.3.2. Immunosuppressants

        11.3.3. Anti-inflammatory Agents

        11.3.4. Antibiotics

        11.3.5. Analgesics

        11.3.6. Others

    11.4. Europe Rare Dermatological Disease Treatment Market Value Forecast, by Distribution Channel, 2017–2031

        11.4.1. Hospital Pharmacies

        11.4.2. Retail Pharmacies

        11.4.3. Online Pharmacies

    11.5. Europe Rare Dermatological Disease Treatment Market Value Forecast, by Country/Sub-Region, 2017–2031

        11.5.1. Germany

        11.5.2. U.K.

        11.5.3. France

        11.5.4. Spain

        11.5.5. Italy

        11.5.6. Rest of Europe

    11.6. Europe Rare Dermatological Disease Treatment Market Attractiveness Analysis

        11.6.1. By Major Indication

        11.6.2. By Treatment

        11.6.3. By Distribution Channel

        11.6.4. By Country/Sub-Region

12. Asia Pacific Rare Dermatological Disease Treatment Market Analysis and Forecast

    12.1. Introduction

        12.1.1. Key Findings

    12.2. Asia Pacific Rare Dermatological Disease Treatment Market Value Forecast, by Major Indication, 2017–2031

        12.2.1. Systemic Sclerosis (Scleroderma)

        12.2.2. Epidermolysis Bullosa (EB)

        12.2.3. Pemphigus Vulgaris

        12.2.4. Cutaneous Lupus Erythematosus

    12.3. Asia Pacific Rare Dermatological Disease Treatment Market Value Forecast, by Treatment, 2017–2031

        12.3.1. Corticosteroids

        12.3.2. Immunosuppressants

        12.3.3. Anti-inflammatory Agents

        12.3.4. Antibiotics

        12.3.5. Analgesics

        12.3.6. Others

    12.4. Asia Pacific Rare Dermatological Disease Treatment Market Value Forecast, by Distribution Channel, 2017–2031

        12.4.1. Hospital Pharmacies

        12.4.2. Retail Pharmacies

        12.4.3. Online Pharmacies

    12.5. Asia Pacific Rare Dermatological Disease Treatment Market Value Forecast, by Country/Sub-Region, 2017–2031

        12.5.1. China

        12.5.2. Japan

        12.5.3. India

        12.5.4. Australia & New Zealand

        12.5.5. Rest of Asia Pacific

    12.6. Asia Pacific Rare Dermatological Disease Treatment Market Attractiveness Analysis

        12.6.1. By Major Indication

        12.6.2. By Treatment

        12.6.3. By Distribution Channel

        12.6.4. By Country/Sub-Region

13. Latin America Rare Dermatological Disease Treatment Market Analysis and Forecast

    13.1. Introduction

        13.1.1. Key Findings

    13.2. Latin America Rare Dermatological Disease Treatment Market Value Forecast, by Major Indication, 2017–2031

        13.2.1. Systemic Sclerosis (Scleroderma)

        13.2.2. Epidermolysis Bullosa (EB)

        13.2.3. Pemphigus Vulgaris

        13.2.4. Cutaneous Lupus Erythematosus

    13.3. Latin America Rare Dermatological Disease Treatment Market Value Forecast, by Treatment, 2017–2031

        13.3.1. Corticosteroids

        13.3.2. Immunosuppressants

        13.3.3. Anti-inflammatory Agents

        13.3.4. Antibiotics

        13.3.5. Analgesics

        13.3.6. Others

    13.4. Latin America Rare Dermatological Disease Treatment Market Value Forecast, by Distribution Channel, 2017–2031

        13.4.1. Hospital Pharmacies

        13.4.2. Retail Pharmacies

        13.4.3. Online Pharmacies

    13.5. Latin America Rare Dermatological Disease Treatment Market Value Forecast, by Country/Sub-Region, 2017–2031

        13.5.1. Brazil

        13.5.2. Mexico

        13.5.3. Rest of Latin America

    13.6. Latin America Rare Dermatological Disease Treatment Market Attractiveness Analysis

        13.6.1. By Major Indication

        13.6.2. By Treatment

        13.6.3. By Distribution Channel

        13.6.4. By Country/Sub-Region

14. Middle East & Africa Rare Dermatological Disease Treatment Market Analysis and Forecast

    14.1. Introduction

        14.1.1. Key Findings

    14.2. Middle East & Africa Rare Dermatological Disease Treatment Market Value Forecast, by Major Indication, 2017–2031

        14.2.1. Systemic Sclerosis (Scleroderma)

        14.2.2. Epidermolysis Bullosa (EB)

        14.2.3. Pemphigus Vulgaris

        14.2.4. Cutaneous Lupus Erythematosus

    14.3. Middle East & Africa Rare Dermatological Disease Treatment Market Value Forecast, by Treatment, 2017–2031

        14.3.1. Corticosteroids

        14.3.2. Immunosuppressants

        14.3.3. Anti-inflammatory Agents

        14.3.4. Antibiotics

        14.3.5. Analgesics

        14.3.6. Others

    14.4. Middle East & Africa Rare Dermatological Disease Treatment Market Value Forecast, by Distribution Channel, 2017–2031

        14.4.1. Hospital Pharmacies

        14.4.2. Retail Pharmacies

        14.4.3. Online Pharmacies

    14.5. Middle East & Africa Rare Dermatological Disease Treatment Market Value Forecast, by Country/Sub-Region, 2017–2031

        14.5.1. GCC Countries

        14.5.2. South Africa

        14.5.3. Rest of Middle East & Africa

    14.6. Middle East & Africa Rare Dermatological Disease Treatment Market Attractiveness Analysis

        14.6.1. By Major Indication

        14.6.2. By Treatment

        14.6.3. By Distribution Channel

        14.6.4. By Country/Sub-Region

15. Competition Landscape

    15.1. Company Profiles

        15.1.1. Sanofi

            15.1.1.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.1.1.2. Growth Strategies

            15.1.1.3. SWOT Analysis

        15.1.2. GlaxoSmithKline plc

            15.1.2.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.1.2.2. Growth Strategies

            15.1.2.3. SWOT Analysis

        15.1.3. Novartis AG

            15.1.3.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.1.3.2. Growth Strategies

            15.1.3.3. SWOT Analysis

        15.1.4. Castle Creek Biosciences, Inc.

            15.1.4.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.1.4.2. Growth Strategies

            15.1.4.3. SWOT Analysis

        15.1.5. Merck & Co., Inc.

            15.1.5.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.1.5.2. Growth Strategies

            15.1.5.3. SWOT Analysis

        15.1.6. Bristol-Myers Squibb Company

            15.1.6.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.1.6.2. Growth Strategies

            15.1.6.3. SWOT Analysis

        15.1.7. Pfizer, Inc.

            15.1.7.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.1.7.2. Growth Strategies

            15.1.7.3. SWOT Analysis

        15.1.8. F. Hoffmann-La Roche Ltd.

            15.1.8.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.1.8.2. Growth Strategies

            15.1.8.3. SWOT Analysis

        15.1.9. Merck KGaA

            15.1.9.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.1.9.2. Growth Strategies

            15.1.9.3. SWOT Analysis

        15.1.10. Eli Lilly and Company

            15.1.10.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.1.10.2. Growth Strategies

            15.1.10.3. SWOT Analysis

        15.1.11. AbbVie, Inc.

            15.1.11.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.1.11.2. Growth Strategies

            15.1.11.3. SWOT Analysis

        15.1.12. Krystal Biotech, Inc.

            15.1.12.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.1.12.2. Growth Strategies

            15.1.12.3. SWOT Analysis

        15.1.13. Amryt Pharma plc

            15.1.13.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.1.13.2. Growth Strategies

            15.1.13.3. SWOT Analysis

List of Tables

Table 01: Global Rare Dermatological Disease Treatment Market Value (US$ Mn) Forecast, by Major Indication, 2017–2031

Table 02: Global Rare Dermatological Disease Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017–2031

Table 03: Global Rare Dermatological Disease Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 04: Global Rare Dermatological Disease Treatment Market Value (US$ Mn) Forecast, by Region, 2017–2031

Table 05: North America Rare Dermatological Disease Treatment Market Value (US$ Mn) Forecast, by Country, 2017–2031

Table 06: North America Rare Dermatological Disease Treatment Market Value (US$ Mn) Forecast, by Major Indication, 2017–2031

Table 07: North America Rare Dermatological Disease Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017–2031

Table 08: North America Rare Dermatological Disease Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 09: Europe Rare Dermatological Disease Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 10: Europe Rare Dermatological Disease Treatment Market Value (US$ Mn) Forecast, by Major Indication, 2017–2031

Table 11: Europe Rare Dermatological Disease Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017–2031

Table 12: Europe Rare Dermatological Disease Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 13: Asia Pacific Rare Dermatological Disease Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 14: Asia Pacific Rare Dermatological Disease Treatment Market Value (US$ Mn) Forecast, by Major Indication, 2017–2031

Table 15: Asia Pacific Rare Dermatological Disease Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017–2031

Table 16: Asia Pacific Rare Dermatological Disease Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 17: Latin America Rare Dermatological Disease Treatment Market Value (US$ Mn) Forecast, by Country, 2017–2031

Table 18: Latin America Rare Dermatological Disease Treatment Market Value (US$ Mn) Forecast, by Major Indication, 2017–2031

Table 19: Latin America Rare Dermatological Disease Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017–2031

Table 20: Latin America Rare Dermatological Disease Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 21: Middle East & Africa Rare Dermatological Disease Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 22: Middle East & Africa Rare Dermatological Disease Treatment Market Value (US$ Mn) Forecast, by Major Indication, 2017–2031

Table 23: Middle East & Africa Rare Dermatological Disease Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017–2031

Table 24: Middle East & Africa Rare Dermatological Disease Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

List of Figures

Figure 01: Rare Dermatological Disease Treatment Market Value (US$ Mn) Forecast, 2017–2031

Figure 02: Rare Dermatological Disease Treatment Market Value Share, by Major Indication, 2020

Figure 03: Rare Dermatological Disease Treatment Market Value Share, by Treatment, 2020

Figure 04: Rare Dermatological Disease Treatment Market Value Share, by Distribution Channel, 2020

Figure 05: Global Rare Dermatological Disease Treatment Market Value Share Analysis, by Major Indication, 2020 and 2031

Figure 06: Global Rare Dermatological Disease Treatment Market Attractiveness Analysis, by Major Indication, 2021–2031

Figure 07: Global Rare Dermatological Disease Treatment Market Revenue (US$ Mn), by Systemic Sclerosis (Scleroderma), 2017–2031

Figure 08: Global Rare Dermatological Disease Treatment Market Revenue (US$ Mn), by Epidermolysis Bullosa (EB), 2017–2031

Figure 09: Global Rare Dermatological Disease Treatment Market Revenue (US$ Mn), by Pemphigus Vulgaris, 2017–2031

Figure 10: Global Rare Dermatological Disease Treatment Market Revenue (US$ Mn), by Cutaneous Lupus Erythematosus, 2017–2031

Figure 11: Global Rare Dermatological Disease Treatment Market Value Share Analysis, by Treatment, 2020 and 2031

Figure 12: Global Rare Dermatological Disease Treatment Market Attractiveness Analysis, by Treatment, 2021–2031

Figure 13: Global Rare Dermatological Disease Treatment Market Revenue (US$ Mn), by Corticosteroids, 2017–2031

Figure 14: Global Rare Dermatological Disease Treatment Market Revenue (US$ Mn), by Immunosuppressants, 2017–2031

Figure 15: Global Rare Dermatological Disease Treatment Market Revenue (US$ Mn), by Anti-inflammatory Agents, 2017–2031

Figure 16: Global Rare Dermatological Disease Treatment Market Revenue (US$ Mn), by Antibiotics, 2017–2031

Figure 17: Global Rare Dermatological Disease Treatment Market Revenue (US$ Mn), by Analgesics, 2017–2031

Figure 18: Global Rare Dermatological Disease Treatment Market Revenue (US$ Mn), by Others, 2017–2031

Figure 19: Global Rare Dermatological Disease Treatment Market Value Share Analysis, by Distribution Channel, 2020 and 2031

Figure 20: Global Rare Dermatological Disease Treatment Market Attractiveness Analysis, by Distribution Channel, 2021–2031

Figure 21: Global Rare Dermatological Disease Treatment Market Revenue (US$ Mn), by Hospital Pharmacies, 2017–2031

Figure 22: Global Rare Dermatological Disease Treatment Market Revenue (US$ Mn), by Retail Pharmacies, 2017–2031

Figure 23: Global Rare Dermatological Disease Treatment Market Revenue (US$ Mn), by Online Pharmacies, 2017–2031

Figure 24: Global Rare Dermatological Disease Treatment Market Value Share Analysis, by Region, 2020 and 2031

Figure 25: Global Rare Dermatological Disease Treatment Market Attractiveness Analysis, by Region, 2021–2031

Figure 26: North America Rare Dermatological Disease Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

Figure 27: North America Rare Dermatological Disease Treatment Market Value Share, by Country, 2020 & 2031

Figure 28: North America Rare Dermatological Disease Treatment Market Attractiveness, by Country, 2021–2031

Figure 29: North America Rare Dermatological Disease Treatment Market Value Share Analysis, by Major Indication, 2020 and 2031

Figure 30: North America Rare Dermatological Disease Treatment Market Attractiveness Analysis, by Major Indication, 2021–2031

Figure 31: North America Rare Dermatological Disease Treatment Market Value Share (%), by Treatment, 2020 and 2031

Figure 32: North America Rare Dermatological Disease Treatment Market Attractiveness, by Treatment, 2021–2031

Figure 33: North America Rare Dermatological Disease Treatment Market Value Share (%), by Distribution Channel, 2020 and 2031

Figure 34: North America Rare Dermatological Disease Treatment Market Attractiveness, by Distribution Channel, 2021–2031

Figure 35: Europe Rare Dermatological Disease Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

Figure 36: Europe Rare Dermatological Disease Treatment Market Value Share, by Country/Sub-region, 2020 & 2031

Figure 37: Europe Rare Dermatological Disease Treatment Market Attractiveness, by Country/Sub-region, 2021–2031

Figure 38: Europe Rare Dermatological Disease Treatment Market Value Share Analysis, by Major Indication, 2020 and 2031

Figure 39: Europe Rare Dermatological Disease Treatment Market Attractiveness Analysis, by Major Indication, 2021–2031

Figure 40: Europe Rare Dermatological Disease Treatment Market Value Share (%), by Treatment, 2020 and 2031

Figure 41: Europe Rare Dermatological Disease Treatment Market Attractiveness, by Treatment, 2021–2031

Figure 42: Europe Rare Dermatological Disease Treatment Market Value Share (%), by Distribution Channel, 2020 and 2031

Figure 43: Europe Rare Dermatological Disease Treatment Market Attractiveness, by Distribution Channel, 2021–2031

Figure 44: Asia Pacific Rare Dermatological Disease Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

Figure 45: Asia Pacific Rare Dermatological Disease Treatment Market Value Share, by Country/Sub-region, 2020 & 2031

Figure 46: Asia Pacific Rare Dermatological Disease Treatment Market Attractiveness, by Country/Sub-region, 2021–2031

Figure 47: Asia Pacific Rare Dermatological Disease Treatment Market Value Share Analysis, by Major Indication, 2020 and 2031

Figure 48: Asia Pacific Rare Dermatological Disease Treatment Market Attractiveness Analysis, by Major Indication, 2021–2031

Figure 49: Asia Pacific Rare Dermatological Disease Treatment Market Value Share (%), by Treatment, 2020 and 2031

Figure 50: Asia Pacific Rare Dermatological Disease Treatment Market Attractiveness, by Treatment, 2021–2031

Figure 51: Asia Pacific Rare Dermatological Disease Treatment Market Value Share (%), by Distribution Channel, 2020 and 2031

Figure 52: Asia Pacific Rare Dermatological Disease Treatment Market Attractiveness, by Distribution Channel, 2021–2031

Figure 53: Latin America Rare Dermatological Disease Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

Figure 54: Latin America Rare Dermatological Disease Treatment Market Value Share, by Country, 2020 & 2031

Figure 55: Latin America Rare Dermatological Disease Treatment Market Attractiveness, by Country, 2021–2031

Figure 56: Latin America Rare Dermatological Disease Treatment Market Value Share Analysis, by Major Indication, 2020 and 2031

Figure 57: Latin America Rare Dermatological Disease Treatment Market Attractiveness Analysis, by Major Indication, 2021–2031

Figure 58: Latin America Rare Dermatological Disease Treatment Market Value Share (%), by Treatment, 2020 and 2031

Figure 59: Latin America Rare Dermatological Disease Treatment Market Attractiveness, by Treatment, 2021–2031

Figure 60: Latin America Rare Dermatological Disease Treatment Market Value Share (%), by Distribution Channel, 2020 and 2031

Figure 61: Latin America Rare Dermatological Disease Treatment Market Attractiveness, by Distribution Channel, 2021–2031

Figure 62: Middle East Rare Dermatological Disease Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

Figure 63: Middle East Rare Dermatological Disease Treatment Market Value Share, by Country/Sub-region, 2020 & 2031

Figure 64: Middle East Rare Dermatological Disease Treatment Market Attractiveness, by Country/Sub-region, 2021–2031

Figure 65: Middle East & Africa Rare Dermatological Disease Treatment Market Value Share Analysis, by Major Indication, 2020 and 2031

Figure 66: Middle East & Africa Rare Dermatological Disease Treatment Market Attractiveness Analysis, by Major Indication, 2021–2031

Figure 67: Middle East & Africa Rare Dermatological Disease Treatment Market Value Share (%), by Treatment, 2020 and 2031

Figure 68: Middle East & Africa Rare Dermatological Disease Treatment Market Attractiveness, by Treatment, 2021–2031

Figure 69: Middle East & Africa Rare Dermatological Disease Treatment Market Value Share (%), by Distribution Channel, 2020 and 2031

Figure 70: Middle East & Africa Rare Dermatological Disease Treatment Market Attractiveness, by Distribution Channel, 2021–2031

Transparency Market Research Plus
  • We offer 100% free customisation with our Enterprise License!!
  • Get a free copy if the report you purchased is updated within 90 days
  • Regardless from where you have purchased the report, you can request an updated version of the report from us.

Complete the form below and we'll get back to you shortly.

375

Your personal details are safe with us. Privacy Policy*

Copyright © Transparency Market Research, Inc. All Rights reserved